Figure 2. Sesn2 inactivation does not affect tumor initiation and life expectancy in tumor-bearing mice but slows down tumor growth.

(A) Tumors from control and Sesn2-deficient mice. 2-month-old Sesn2^+/+;Kras^LSL-G12D and Sesn2^-/-;Kras^LSL-G12D mice were injected with Adeno-Cre intratracheally and analyzed 6 months later. The lung sections were stained with H&E. (B) The total number of tumors in Sesn2^+/+;Kras^LSL-G12D and Sesn2^-/-;Kras^LSL-G12D mice. (C) Sesn2^-/- mice develop tumors of smaller size. In (A–C), 4 mice were analyzed per group. The data in (B) and (C) are presented as mean ± S.D. P values were calculated using two-tailed student’s t-test. (D) Tumor-bearing Sesn2^+/+ and Sesn2^-/- mice have a similar lifespan. The mice (12 animals per each group) were injected with Adeno-Cre as in (A) and the lifespan was examined.